• 1
    Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003; 39: 19902005.
  • 2
    Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med. 1993; 329: 257263.
  • 3
    Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol. 2005; 54: 243250.
  • 4
    Seve P, Stankovic K, Charhon A, Broussolle C. Carcinoma of unknown primary site. Rev Med Intern. 2006; 27: 532545.
  • 5
    Kambhu SA, Kelsen DP, Fiore J, et al. Metastatic adenocarcinomas of unknown primary site. Prognostic variables and treatment results. Am J Clin Oncol. 1990; 13: 5560.
  • 6
    Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol. 1992; 10: 912922.
  • 7
    Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994; 12: 12721280.
  • 8
    van der Gaast A, Verweij J, Planting AS, Hop WC, Stoter G. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol. 1995; 13: 17201725.
  • 9
    Seve P, Sawyer M, Hanson J, Broussolle C, Dumontet C, Mackey JR. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. Cancer. 2006; 106: 20582066.
  • 10
    Culine S, Kramar A, Saghatchian M, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002; 20: 46794683.
  • 11
    Claude L, Perol D, Ray-Coquard I, et al. Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. Radiother Oncol. 2005; 76: 334339.
  • 12
    Pirovano M, Maltoni M, Nanni O, et al. A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. J Pain Symptom Manage. 1999; 17: 231239.
  • 13
    Vigano A, Bruera E, Jhangri GS, Newman SC, Fields AL, Suarez-Almazor ME. Clinical survival predictors in patients with advanced cancer. Arch Intern Med. 2000; 160: 861868.
  • 14
    Maltoni M, Caraceni A, Brunelli C, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations—a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol. 2005; 23: 62406248.
  • 15
    Dixon MR, Haukoos JS, Udani SM, et al. Carcinoembryonic antigen and albumin predict survival in patients with advanced colon and rectal cancer. Arch Surg. 2003; 138: 962966.
  • 16
    Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med. 2000; 161(2 Pt 1): 589594.
  • 17
    Parker D, Bradley C, Bogle SM, et al. Serum albumin and CA125 are powerful predictors of survival in epithelial ovarian cancer. Br J Obstet Gynaecol. 1994; 101: 888893.
  • 18
    Sirott MN, Bajorin DF, Wong GY, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer. 1993; 72: 30913098.
  • 19
    Wyld L, Gutteridge E, Pinder SE, et al. Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer. 2003; 89: 284290.
  • 20
    Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel ELJr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004; 291: 24412447.
  • 21
    Blay JY, Chauvin F, Le Cesne A, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol. 1996; 14: 636643.
  • 22
    Ray-Coquard I, Ghesquiere H, Bachelot T, et al. Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer. 2001; 85: 816822.
  • 23
    Hainsworth JD, Erland JB, Kalman LA, Schreeder MT, Greco FA. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol. 1997; 15: 23852393.
  • 24
    Greco FA, Burris HA3rd, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2002; 20: 16511656.
  • 25
    Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res. 1999; 5: 34033410.
  • 26
    van de Wouw AJ, Jansen RL, Griffioen AW, Hillen HF. Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res. 2004; 24: 297301.
  • 27
    Hussain M, Kish JA, Crane L, et al. The role of infection in the morbidity and mortality of patients with head and neck cancer undergoing multimodality therapy. Cancer. 1991; 67: 716721.
  • 28
    Saito T, Dworacki G, Gooding W, Lotze MT, Whiteside TL. Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res. 2000; 6: 13511364.
  • 29
    Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer. 2002; 87: 264267.
  • 30
    Al-Shaiba R, McMillan DC, Angerson WJ, Leen E, McArdle CS, Horgan P. The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases. Br J Cancer. 2004; 91: 205207.
  • 31
    McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer. 2001; 41: 6469.
  • 32
    McMillan DC, Watson WS, O'Gorman P, Preston T, Scott HR, McArdle CS. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 2001; 39: 210213.